WO2021236116A1 - Antiviral medicinal template - Google Patents

Antiviral medicinal template Download PDF

Info

Publication number
WO2021236116A1
WO2021236116A1 PCT/US2020/035030 US2020035030W WO2021236116A1 WO 2021236116 A1 WO2021236116 A1 WO 2021236116A1 US 2020035030 W US2020035030 W US 2020035030W WO 2021236116 A1 WO2021236116 A1 WO 2021236116A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
virus
genome
question
template
Prior art date
Application number
PCT/US2020/035030
Other languages
French (fr)
Inventor
Kevin DELAHOUSSAYE
Original Assignee
Delahoussaye Kevin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delahoussaye Kevin filed Critical Delahoussaye Kevin
Publication of WO2021236116A1 publication Critical patent/WO2021236116A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

Definitions

  • the blood should contain part of/the whole genome of the virus in question.
  • Modulated PCR techniques would allow for the differentiation of the genetic material from the rest of the container of blood.
  • Regular PCR should be done to create copies of the genome /parts of the genome of the virus in question. This should produce a therapeutic and a potential vaccine.

Abstract

Draw blood from the infected individual. The blood should contain part of/the whole genome of the virus in question. Modulated PCR techniques would allow for the differentiation of the genetic material from the rest of the container of blood. Regular PCR should be done to create copies of the genome /parts of the genome of the virus in question. This should produce a therapeutic and a potential vaccine. With different strains of the virus the persons own infected blood can be used. Information left out due to my policy.

Description

(A) Specification
Antiviral medicinal template
B: Cross Reference to Related Applications: Not Applicable
( C ) Regarding Federally Sponsored Research or Development: Not Applicable
( D): Regarding The Names of The Parties To a Joint Research Agreement:
Not Applicable
E: incorporation by reference of material submitted on a compact disc or as a text file via the The Office Electronic Filing System (EFS-Web):
F: Statement Regarding Prior Disclosures by The Inventor Or a Joint inventor: Not Applicable
G: Background of invention:
(1): Pandemic occurring at the time of filing. Virology, Physics, PCR, Biology, Chemistry, creativity.
(H): Brief Summary of Invention: Draw blood from the infected individual. The blood should contain part of/the whole genome of the virus in question. Modulated PCR techniques would allow for the differentiation of the genetic material from the rest of the container of blood. Regular PCR should be done to create copies of the genome /parts of the genome of the virus in question. This should produce a therapeutic and a potential vaccine.
With different strains of the virus the persons own infected blood can be used.
(K): Claim or Claims: See Document "Claims"
(L): Abstract of Disclosure: See Document "Abstract"
(M): Sequence Listing: Not Applicable

Claims

Antiviral medicinal template:
Claims: l:Draw blood from the infected individual. The blood should contain part of/the whole genome of the virus in question.
II: Modulated PCR techniques would allow for the differentiation of the genetic material from the rest of the container of blood
III: Regular PCR should be done to create copies of the genome /parts of the genome of the virus in question. This should produce a therapeutic and a potential vaccine;With different strains of the virus the persons own infected blood can be used.
PCT/US2020/035030 2020-05-20 2020-05-29 Antiviral medicinal template WO2021236116A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063027918P 2020-05-20 2020-05-20
US63/027,918 2020-05-20

Publications (1)

Publication Number Publication Date
WO2021236116A1 true WO2021236116A1 (en) 2021-11-25

Family

ID=78707992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/035030 WO2021236116A1 (en) 2020-05-20 2020-05-29 Antiviral medicinal template

Country Status (1)

Country Link
WO (1) WO2021236116A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072211A1 (en) * 2005-06-30 2007-03-29 Roche Molecular Systems, Inc. Asymmetric PCR coupled with post-PCR characterization for the identification of nucleic acids
WO2007094854A2 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma Rna virus vaccines and methods
US20160047006A1 (en) * 2010-04-23 2016-02-18 Genomic Vision Diagnosis of viral infections by detection of genomic and infectious viral dna by molecular combing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072211A1 (en) * 2005-06-30 2007-03-29 Roche Molecular Systems, Inc. Asymmetric PCR coupled with post-PCR characterization for the identification of nucleic acids
WO2007094854A2 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma Rna virus vaccines and methods
US20160047006A1 (en) * 2010-04-23 2016-02-18 Genomic Vision Diagnosis of viral infections by detection of genomic and infectious viral dna by molecular combing

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARTER ET AL.: "Assay Techniques and Test Development for COVID-19 Diagnosis", ACS CENTRAL SCIENCE, vol. 6, 30 April 2020 (2020-04-30), pages 591 - 605, XP055822886, DOI: 10.1021/acscentsci.0c00501 *
CHIEN ET AL.: "Development of Real-Time Reverse Transcriptase PCR Assays To Detect and Serotype Dengue Viruses", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 44, 5 April 2006 (2006-04-05), pages 1295 - 1304, XP009139728, DOI: 10.1128/JCM.44.4.1295�1304.2006 *

Similar Documents

Publication Publication Date Title
Krupovic et al. Ortervirales: new virus order unifying five families of reverse-transcribing viruses
Ashley et al. Interferon-independent upregulation of interferon-stimulated genes during human cytomegalovirus infection is dependent on IRF3 expression
Farshidfar et al. Hyposalivation as a potential risk for SARS‐CoV‐2 infection: inhibitory role of saliva
Clements-Mann et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults
Notkins et al. Concepts in viral pathogenesis II
Chen et al. CRISPR-Cas targeting of host genes as an antiviral strategy
Chulpanova et al. Recombinant viruses for cancer therapy
JP2017527557A5 (en)
Méric et al. From Escherich to the Escherichia coli genome
Escalante et al. A pentavalent Epstein-Barr virus-like particle vaccine elicits high titers of neutralizing antibodies against Epstein-Barr virus infection in immunized rabbits
Sivaraman et al. Type I interferon contributes to CD4+ T cell depletion induced by infection with HIV-1 in the human thymus
Oliveira et al. Promoter motifs in NCLDVs: an evolutionary perspective
WO2021236116A1 (en) Antiviral medicinal template
Lakis et al. Novel poxvirus infection in an immune suppressed patient
Coffin et al. Clonal expansion of infected CD4+ T cells in people living with HIV
Becker et al. Molecular aspects of human cytomegalovirus diseases
Murphy et al. An RNA-directed gene editing strategy for attenuating the infectious potential of feline immunodeficiency virus-infected cells: a proof of concept
Hamann et al. Foamy virus protein—nucleic acid interactions during particle morphogenesis
JP2015518716A5 (en)
Torbett et al. The Future of HIV-1 Therapeutics: Resistance Is Futile?
Letvin et al. Simian immunodeficiency virus
Calisher 100 Years of Virology The Birth and Growth of a Discipline
Warrilow et al. Complete coding sequences of three members of the kokobera group of flaviviruses
Bukrinsky How to engage Cofilin
Murahwa et al. Complete genome sequences of four novel human Gammapapillomavirus types, HPV-219, HPV-220, HPV-221, and HPV-222, isolated from penile skin swabs from south African men

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20936843

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20936843

Country of ref document: EP

Kind code of ref document: A1